Ástralía - enska - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - potassium clavulanate, quantity: 151.917 mg; amoxicillin trihydrate, quantity: 573.892 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; dichloromethane; isopropyl alcohol; sodium starch glycollate; titanium dioxide; hypromellose; propylene glycol; purified talc; ethylcellulose - amclavox duo 500/125 tablets are indicated for short-term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (complicated and uncomplicated),lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis,upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.,skin and skin structure infection.,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxicillin and clavulanic acid tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxicillin and clavulanic acid tablets preparations should not require the addition of another antibiotic due to the amoxicillin content of these products.

Bandaríkin - enska - NLM (National Library of Medicine)

deseret biologicals, inc. - sodium borate (unii: 91mbz8h3qo) (borate ion - unii:44oae30d22), bryonia alba root (unii: t7j046yi2b) (bryonia alba root - unii:t7j046yi2b), echinacea purpurea whole (unii: qi7g114y98) (echinacea purpurea - unii:qi7g114y98), juglans cinerea branch bark/root bark (unii: 48fz1bho18) (juglans cinerea branch bark/root bark - unii:48fz1bho18), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152), magnesium chloride (unii: 02f3473h9o) (magnesium cation - unii:t6v3lhy838), hydrochloric acid (unii: qtt17582cb) (hydrochloric acid - unii:qtt17582cb), sus scrofa intervertebral disc (unii: oj17o2wtsm) (sus scrofa intervertebral disc - unii:oj17o2wtsm), sus scrofa oral mucosa (unii: dup6w562bm) (sus scrofa oral mucosa - unii:dup6w562bm), antimony trisulfide (unii: f79059a38u) (antimony trisulfide - unii:f79059a38u), arsenic trioxide (unii: s7v92p67ho) (arsenic cation (3+) - unii:c96613f5av), bismuth subnitrate (unii: h19j064ba5) (bismuth cation - unii:zs9cd1i8ye), matricaria chamomilla whole (unii: g0r4ubi2zz) (matricaria chamomilla - unii:g0r4ubi2zz), cinchona officinalis bark (unii: s003a158sb) (cinchona officinalis bark - unii:s003a158sb), nutmeg (unii: aee24m3mq9) (nutmeg - unii:aee24m3mq9), sambucus nigra flowering top (unii: ct03bsa18u) (sambucus nigra flowering top - unii:ct03bsa18u), sepia officinalis juice (unii: qdl83wn8c2) (sepia officinalis juice - unii:qdl83wn8c2), mercurius solubilis (unii: 324y4038g2) (mercurius solubilis - unii:324y4038g2), tribasic calcium phosphate (unii: 91d9gv0z28) (calcium cation - unii:2m83c4r6zb), strychnos ignatii seed (unii: 1nm3m2487k) (strychnos ignatii seed - unii:1nm3m2487k), oxygen (unii: s88tt14065) (oxygen - unii:s88tt14065), candida albicans (unii: 4d7g21hdbc) (candida albicans - unii:4d7g21hdbc), staphylococcus aureus (unii: o478wx4004) (staphylococcus aureus - unii:o478wx4004), streptococcus mutans (unii: 5c7j33mjj1) (streptococcus mutans - unii:5c7j33mjj1) - for the temporary relief of symptoms related to oral health, such as cavitation, delayed dentition, dry mouth, painful eating, eruptions on tongue and inner cheeks and tooth sensitivity.** **these statements are based upon homeopathic principles. they have not been reviewed by the food and drug administration. for the temporary relief of symptoms related to oral health, such as cavitation, delayed dentition, dry mouth, painful eating, eruptions on tongue and inner cheeks and tooth sensitivity.** **these statements are based upon homeopathic principles. they have not been reviewed by the food and drug administration.

Bandaríkin - enska - NLM (National Library of Medicine)

deseret biologicals, inc. - antimony trisulfide (unii: f79059a38u) (antimony trisulfide - unii:f79059a38u), arsenic trioxide (unii: s7v92p67ho) (arsenic cation (3+) - unii:c96613f5av), bismuth subnitrate (unii: h19j064ba5) (bismuth cation - unii:zs9cd1i8ye), sodium borate (unii: 91mbz8h3qo) (borate ion - unii:44oae30d22), bryonia alba root (unii: t7j046yi2b) (bryonia alba root - unii:t7j046yi2b), tribasic calcium phosphate (unii: 91d9gv0z28) (calcium cation - unii:2m83c4r6zb), candida albicans (unii: 4d7g21hdbc) (candida albicans - unii:4d7g21hdbc), matricaria chamomilla whole (unii: g0r4ubi2zz) (matricaria chamomilla - unii:g0r4ubi2zz), cinchona officinalis bark (unii: s003a158sb) (cinchona officinalis bark - unii:s003a158sb), sus scrofa intervertebral disc (unii: oj17o2wtsm) (sus scrofa intervertebral disc - unii:oj17o2wtsm), herring sperm dna (unii: 51fi676n6f) (herring sperm dna - unii:51fi676n6f), echinacea purpurea whole (unii: qi7g114y98) (echinacea purpurea - unii:qi7g114y98), strychnos ignatii seed (unii: 1nm3m2487k) (strychnos ignatii seed - unii:1nm3m2487k), juglans cinerea branch bark/root bark (unii: 48fz1bho18) (juglans cinerea branch bark/root bark - unii:48fz1bho18), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152), magnesium chloride (unii: 02f3473h9o) (magnesium cation - unii:t6v3lhy838), mercurius solubilis (unii: 324y4038g2) (mercurius solubilis - unii:324y4038g2), hydrochloric acid (unii: qtt17582cb) (hydrochloric acid - unii:qtt17582cb), nutmeg (unii: aee24m3mq9) (nutmeg - unii:aee24m3mq9), sus scrofa oral mucosa (unii: dup6w562bm) (sus scrofa oral mucosa - unii:dup6w562bm), oxygen (unii: s88tt14065) (oxygen - unii:s88tt14065), sambucus nigra flowering top (unii: ct03bsa18u) (sambucus nigra flowering top - unii:ct03bsa18u), sepia officinalis juice (unii: qdl83wn8c2) (sepia officinalis juice - unii:qdl83wn8c2), staphylococcus aureus (unii: o478wx4004) (staphylococcus aureus - unii:o478wx4004), streptococcus mutans (unii: 5c7j33mjj1) (streptococcus mutans - unii:5c7j33mjj1) - antimonium crudum – mouth support, arsenicum album – dental support, bismuthum subnitricum – pain in ears, borax – dry mouth, bryonia (alba) – eruption on tongue, calcarea phosphorica – dental issues, candida albicans – eruption on cheeks, chamomilla – teeth sensitivity, cinchona officinalis – mouth support, discus intervertebralis suis – dry mouth, dna – mouth support, echinacea purpurea – mouth support, ignatia amara – teeth sensitivity, juglans cinerea – pain in ears, kali muriaticum – eruption on tongue, magnesia muriatica – dental support, mercurius solubilis – teeth sensitivity, muriaticum acidum – dry mouth, nux moschata – dry mouth, oral mucosa (suis) – mouth support, oxygenium – eruption on tongue, sambucus nigra – dry mouth, sepia – teeth sensitivity, staphylococcus aureus – mouth support, streptococcus mutans – mouth support • for the temporary relief of symptoms including: • mouth support • teeth sensitivity • dental issues • dental support • pain in ears • eruption on tongue • eruption on cheeks • dry mouth these statements are based upon homeopathic principles. they have not been reviewed by the food and drug administration.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - potassium clavulanate, quantity: 151.917 mg; amoxicillin trihydrate, quantity: 1004.31 mg - tablet, film coated - excipient ingredients: isopropyl alcohol; sodium starch glycollate; dichloromethane; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; titanium dioxide; hypromellose; propylene glycol; purified talc; ethylcellulose - amoxyclav b&b 875/125 tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (complicated and uncomplicated),lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis.,upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.,skin and skin structure infections.,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxicillin and clavulanic acid tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxicillin and clavulanic acid tablets preparations should not require the addition of another antibiotic due to the amoxicillin content of these products.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - potassium clavulanate, quantity: 151.917 mg; amoxicillin trihydrate, quantity: 1004.31 mg - tablet, film coated - excipient ingredients: dichloromethane; isopropyl alcohol; microcrystalline cellulose; sodium starch glycollate; magnesium stearate; colloidal anhydrous silica; titanium dioxide; hypromellose; propylene glycol; purified talc; ethylcellulose - amoxyclav mlabs 875/125 tablets are indicated for short-term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (complicated and uncomplicated),lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis,upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.,skin and skin structure infection.,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxicillin and clavulanic acid tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxicillin and clavulanic acid tablets preparations should not require the addition of another antibiotic due to the amoxicillin content of these products.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - potassium clavulanate, quantity: 151.917 mg; amoxicillin trihydrate, quantity: 573.892 mg - tablet, film coated - excipient ingredients: isopropyl alcohol; colloidal anhydrous silica; magnesium stearate; sodium starch glycollate; dichloromethane; microcrystalline cellulose; titanium dioxide; hypromellose; propylene glycol; purified talc; ethylcellulose - amoxyclav mlabs 500/125 tablets are indicated for short-term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (complicated and uncomplicated),lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis,upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.,skin and skin structure infection.,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxicillin and clavulanic acid tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxicillin and clavulanic acid tablets preparations should not require the addition of another antibiotic due to the amoxicillin content of these products.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - amoxicillin trihydrate, quantity: 1004.31 mg; potassium clavulanate, quantity: 151.917 mg - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; dichloromethane; microcrystalline cellulose; sodium starch glycollate; isopropyl alcohol; titanium dioxide; hypromellose; propylene glycol; purified talc; ethylcellulose - amclavox duo forte 875/125 tablets are indicated for short-term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (complicated and uncomplicated),lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis,upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.,skin and skin structure infection.,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxicillin and clavulanic acid tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxicillin and clavulanic acid tablets preparations should not require the addition of another antibiotic due to the amoxicillin content of these products.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - potassium clavulanate, quantity: 151.917 mg; amoxicillin trihydrate, quantity: 1004.31 mg - tablet, film coated - excipient ingredients: isopropyl alcohol; sodium starch glycollate; dichloromethane; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; titanium dioxide; hypromellose; propylene glycol; purified talc; ethylcellulose - amoxyclav b&b 875/125 tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (complicated and uncomplicated),lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis.,upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.,skin and skin structure infections.,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxicillin and clavulanic acid tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxicillin and clavulanic acid tablets preparations should not require the addition of another antibiotic due to the amoxicillin content of these products.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - potassium clavulanate, quantity: 151.917 mg; amoxicillin trihydrate, quantity: 1004.31 mg - tablet, film coated - excipient ingredients: dichloromethane; isopropyl alcohol; microcrystalline cellulose; sodium starch glycollate; magnesium stearate; colloidal anhydrous silica; titanium dioxide; hypromellose; propylene glycol; purified talc; ethylcellulose - amoxyclav mlabs 875/125 tablets are indicated for short-term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (complicated and uncomplicated),lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis,upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.,skin and skin structure infection.,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxicillin and clavulanic acid tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxicillin and clavulanic acid tablets preparations should not require the addition of another antibiotic due to the amoxicillin content of these products.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - potassium clavulanate, quantity: 151.917 mg; amoxicillin trihydrate, quantity: 573.892 mg - tablet, film coated - excipient ingredients: isopropyl alcohol; colloidal anhydrous silica; magnesium stearate; sodium starch glycollate; dichloromethane; microcrystalline cellulose; titanium dioxide; hypromellose; propylene glycol; purified talc; ethylcellulose - amoxyclav mlabs 500/125 tablets are indicated for short-term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (complicated and uncomplicated),lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis,upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.,skin and skin structure infection.,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxicillin and clavulanic acid tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxicillin and clavulanic acid tablets preparations should not require the addition of another antibiotic due to the amoxicillin content of these products.